Trial Profile
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- Acronyms GO-LEVEL
- 07 Jun 2020 Results identifying optimal serum golimumab concentration thresholds during induction and maintenance treatment with golimumab published in the Alimentary Pharmacology and Therapeutics
- 19 May 2020 Results (n=104) assessing exposure-response relationship from induction and maintenance cohort published in Gasteroenterology in conjunction with Digestive Disease Week 2020
- 04 Feb 2020 Status changed from recruiting to completed.